Key result
A high ORBIT score was independently associated with increased 30-day mortality in patients with STEMI (HR 1.309; 95% CI 1.101-1.556; P=0.013).
Why the study?
The ORBIT score assesses bleeding risk in AF, but its potential correlation with 30-day mortality in patients with STEMI was unknown.
Does the ORBIT score predict 30-day mortality in patients with STEMI?
Cohort (n=639)
Does the ORBIT score predict 30-day mortality in patients with STEMI?
Hazard Ratio: 1.309 (95% CI 1.101–1.556)
p-value: p=.013
The ORBIT score, originally designed to assess bleeding risk in atrial fibrillation, is an independent predictor of 30-day mortality in patients with STEMI.
A new scoring system Outcomes Registry for Better Informed Treatment (ORBIT) score is used to assess the bleeding risk in anticoagulated patients with atrial fibrillation (AF). Our aim is to investigate the possible correlations of the ORBIT score with 30-day mortality in patients with ST-segment elevation myocardial infarction (STEMI). A total of 639 patients with STEMI were enrolled in this study. The ORBIT, HAS-BLED, and TIMI scores were recorded during admission. After 30 days’ follow-up, 639 patients were divided into 2 groups: the survival group and the nonsurvival group. Different clinical parameters were compared. The predictive values of the ORBIT, HAS-BLED, and TIMI scores for 30-day mortality were assessed from receiver operating characteristic (ROC) analyses. The univariate and multivariate Cox proportional hazards analyses were applied to evaluate the relationships between variables and 30-day mortality. Sixty-seven deaths occurred after a 30-day follow-up. The ORBIT, HAS-BLED, and TIMI scores in the death group were higher than those in the survival group ( P < .05). The areas under the ROC curve for the ORBIT, HAS-BLED, and TIMI scores to predict the occurrence of 30-day mortality were 0.811 (95% CI: 0.779-0.841, P < .0001), 0.717 (95% CI: 0.680-0.752, P < .0001), and 0.844 (95% CI: 0.813-0.871, P < .0001), respectively. In multivariate Cox proportional hazards modeling, the high ORBIT score was positively associated with 30-day mortality (hazard ratio: 1.309, 95% CI: 1.101-1.556, P = .013) after adjustment. A graded relation is found in the elevated ORBIT score and 30-day mortality in patients with STEMI. Thus, the ORBIT score can be an independent predictor of 30-day mortality in patients with STEMI.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2020) conducted a cohort in ST-segment elevation myocardial infarction (STEMI) (n=639). High ORBIT score vs. Low ORBIT score was evaluated on 30-day mortality (HR 1.309, 95% CI 1.101-1.556, p=.013). A high ORBIT score was independently associated with increased 30-day mortality in patients with STEMI (HR 1.309; 95% CI 1.101-1.556; P=0.013).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: